Therapeutic Solutions International Stock Surges After This Positive News

Over the course of the past few months, many companies that have been working on medicines or vaccines related to coronavirus have seen their stocks soar and on Wednesday, it was the turn of Therapeutic Solutions International Inc (OTCMKTS:TSOI). 

$XTRM – Exclusive interview with Extreme Biodiesel Inc. a promising real estate business

Unexpected Findings of Synergy 

However, in the case of TSI, the situation was different as the company actually came up with its breakthrough accidentally. After the news broke about it, the stock jumped by as much as 31% as investors piled on to the stock. In such a situation, it could be worthwhile for investors to take a closer look at the company and its business. 

The company announced on Tuesday that it was going to file a patent for a combination of QuadraMune and the antidiabetic medicine metformin as a possible treatment for those suffering from COVID 19 related lung damage. The company found that QuadraMune demonstrated the capability of protecting a person from lung inflammation that closely resembles the sort of inflammation that is brought about by COVID 19. 

The Chief Medical Officer of the company Dr. James Veltmeyer stated that TSI is currently making preparations to conduct a study with 500 people who are at high risk of infection. It is a massive development for the company and if successful, it could propel TSI as well as its stock to new heights. 

The rally in the stock on Wednesday was hence understandable and it is likely that the stock is going to be in focus among numerous investors for the rest of the week. The TSI stock has certainly emerged as one of the more exciting options for those who are looking to invest in small caps and in recent days, the stock has displayed high trading volumes as well. 

Since many new investors have piled on to the stock, the stock’s volume has been robust and a lot of accumulation is going on at this point as TSI prepares for the QuadMune trial. The company, which is based out of California, is expected to be in sharp focus over the coming days in anticipation of this trial and it is quite possible that more accumulation in the stock might take place in the coming days. 

However, QuadMune is not the only product that is the company’s hope with regard to tackling the coronavirus pandemic. Earlier on in July, the company had announced that it had submitted the publication of preclinical data which supports the revaluation of its cancer immunotherapy product StemVacs for the treatment of COVID 19 patients. 

It goes without saying that it is another major development for the company and opens up another pathway for TSI to get involved in tackling the coronavirus pandemic. It also makes the stock a bit more attractive as a potential coronavirus play.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.